BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Takami T, Yamasaki T, Saeki I, Matsumoto T, Suehiro Y, Sakaida I. Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function. World J Gastroenterol 2016; 22(32): 7252-7263 [PMID: 27621572 DOI: 10.3748/wjg.v22.i32.7252] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Zheng W, Yao M, Qian Q, Sai W, Qiu L, Yang J, Wu W, Dong Z, Yao D. Oncogenic secretory clusterin in hepatocellular carcinoma: Expression at early staging and emerging molecular target. Oncotarget 2017;8:52321-32. [PMID: 28881732 DOI: 10.18632/oncotarget.13674] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
2 Bellotti D, Remelli M. Deferoxamine B: A Natural, Excellent and Versatile Metal Chelator. Molecules 2021;26:3255. [PMID: 34071479 DOI: 10.3390/molecules26113255] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Yang WS, Zeng XF, Liu ZN, Zhao QH, Tan YT, Gao J, Li HL, Xiang YB. Diet and liver cancer risk: a narrative review of epidemiological evidence. Br J Nutr 2020;124:330-40. [PMID: 32234090 DOI: 10.1017/S0007114520001208] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
4 Lee JW, Hwang SH, Kim HJ, Kim D, Cho A, Yun M. Volumetric parameters on FDG PET can predict early intrahepatic recurrence-free survival in patients with hepatocellular carcinoma after curative surgical resection. Eur J Nucl Med Mol Imaging. 2017;44:1984-1994. [PMID: 28695236 DOI: 10.1007/s00259-017-3764-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
5 Ruiz-Margáin A, Román-Calleja BM, Moreno-Guillén P, González-Regueiro JA, Kúsulas-Delint D, Campos-Murguía A, Flores-García NC, Macías-Rodríguez RU. Nutritional therapy for hepatocellular carcinoma. World J Gastrointest Oncol 2021; 13(10): 1440-1452 [PMID: 34721776 DOI: 10.4251/wjgo.v13.i10.1440] [Reference Citation Analysis]
6 Peng H, Wang Y, Luo W. Multifaceted role of branched-chain amino acid metabolism in cancer. Oncogene 2020;39:6747-56. [PMID: 32978521 DOI: 10.1038/s41388-020-01480-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
7 Gray JP, Suhali-amacher N, Ray SD. Metals and Metal Antagonists. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. Elsevier; 2017. pp. 197-208. [DOI: 10.1016/bs.seda.2017.07.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Saeki I, Yamasaki T, Yamauchi Y, Takami T, Kawaoka T, Uchikawa S, Hiramatsu A, Aikata H, Kawano R, Kobayashi K, Kondo T, Ogasawara S, Chiba T, Chayama K, Kato N, Sakaida I. Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib Treatment Failure for Hepatocellular Carcinoma. Cancers (Basel) 2021;13:2247. [PMID: 34067075 DOI: 10.3390/cancers13092247] [Reference Citation Analysis]
9 Duan YM, Jin Y, Guo ML, Duan LX, Wang JG. Differentially expressed genes of HepG2 cells treated with gecko polypeptide mixture. J Cancer 2018;9:2723-33. [PMID: 30087713 DOI: 10.7150/jca.26339] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
10 Saeki I, Yamasaki T, Maeda M, Kawano R, Hisanaga T, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Sakaida I. No Muscle Depletion with High Visceral Fat as a Novel Beneficial Biomarker of Sorafenib for Hepatocellular Carcinoma. Liver Cancer 2018;7:359-71. [PMID: 30488024 DOI: 10.1159/000487858] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]